AlkalizeForHealth
"The doctor of the future will give no medicine, but will interest his patients in the care of the human frame, in diet and in the cause and prevention of disease."
- Thomas Edison
Stem cells hidden cause of
cancer. Bone marrow stem cells cause stomach cancer.
The rare childhood cancer called retinoblastoma exhibit various markers and
behaviors more characteristic of cells from an embryo. For example, these
cells form tiny 'microspheres,' just as typical stem cells do. "Generally
speaking, it is only the
cancer stem cell
that perpetuates itself indefinitely and is capable of forming new tumors or
metastases." Learn more about trophoblast cells and cancer. Read about enzymes and cancer.
You can grow
feverfew in your
garden.
Vitamin A Produces Astonishing
Leukemia
Cure Rate, Even Without Chemotherapy. |
-------------------------------------------------------
Ralph W. Moss, Ph.D. Weekly CancerDecisions.com
Newsletter #178 04/03/05
-------------------------------------------------------
THE MOSS REPORTS
In this week's and next week's newsletters I discuss research that unexpectedly brings together an old-fashioned cottage garden favorite, feverfew, and an equally old-fashioned - but suddenly highly topical and increasingly plausible - theory of cancer's ultimate origin.
It has been said, humorously, that no scientific theory gains public acceptance until it has been thoroughly discredited.
For almost a hundred years the ideas of the Scottish embryologist John Beard concerning the origin of cancer have languished in the dusty stack rooms of medical history, spurned by modern oncology in favor of newer theories. But increasingly it is becoming apparent that long before molecular biology was born, Beard may have hit upon a core truth.
In this week's newsletter I discuss new research that indicates that stem cells may ultimately lie at the root of many kinds of cancer. While Beard himself would not have been aware of the existence of stem cells, his theory concerning the origins of cancer is remarkably compatible with the concept of stem cells as the source of malignancy.
It is also curiously satisfying, in a way, that it should be an extract of the humble feverfew that researchers have found to be lethal to the malignant stem cells that cause acute and chronic myelogenous leukemia. The use of botanical extracts in medicine is as old as medicine itself, and it is encouraging to see that their potential is once again being harnessed for the benefit of cancer patients.
For thirty years I have been studying and writing about cancer treatments, both conventional and alternative. The fruit of my long career in this field is The Moss Reports, a comprehensive library of more than two hundred individual reports on specific cancer diagnoses. For cancer patients, a Moss Report represents an invaluable guide and handbook for the journey ahead.
If you would like to order a Moss Report for yourself or someone you love, you can do so from our
website, or by calling Diane at 1-800-980-1234 (814-238-3367 from outside the US).
We look forward to helping you.
FEVERFEW AND CANCER, PART I
Many readers know the feverfew plant (Tanacetum parthenium), a member of the Chrysanthemum family, sometimes called bachelor's buttons. This is a cheerful-looking perennial, with a profusion of white pompon-like blooms-like a shower of tiny daisies. Feverfew is often included in mixed bouquets and, to me, is the essence of summer.
Others know this plant as a source of herbal relief. One traditional usage, as a febrifuge (or fever-reducer) is apparent from its name. It is also a well-known folk remedy for migraine. I keep a feverfew product in my medicine chest, in anticipation of the summertime visits of a friend who is prone to these massive headaches (Pfaffenrath 2002; Murphy 1988.)
Now scientists at the Univeristy of Rochester Medical Center have found that an extract of feverfew is effective against a type of human leukemia. Monica L. Guzman, PhD, and Craig T. Jordan, PhD, report that feverfew extracts kill malignant stem cells like no other single therapy they have tested. The active ingredient is derived from parthenolide, one of a class of sesquiterpene lactones found in the plant. The US National Cancer Institute is sufficiently excited by this work to have accepted it into the rapid access program, which aims to move experimental drugs from the laboratory to human clinical trials as quickly as possible.
"This research is a very important step in setting the stage for future development of a new therapy for leukemia," said Dr. Jordan. "We have proof that we can kill leukemia stem cells with this type of agent, and that is good news."
A Focus on Stem Cells
What is particularly exciting is that this feverfew extract is the first agent known to destroy myeloid leukemia at the level of the stem cells. Increasingly, cancer research is homing in on these primordial cells as the source of cancer. This is the level at which malignancy is born, and unless it is attacked at this level it can rarely be controlled, much less cured.
In the 19th century there were many intimations that primitive cells, called "embryonal rests," were fundamentally connected with the development of cancer. A high point came over a century ago, when University of Edinburgh, Scotland, embryologist John Beard, DSc (1858-1924) put forward the theory that cancer was in fact caused by the malignant transformation of what he called pluripotent germ cells. It now seems almost certain that Beard was giving an early description of stem cells and their propensity to undergo malignant change. Beard's idea was initially greeted with interest, but was later marginalized, and finally all but forgotten. However, his philosophy was kept alive through the work of a few maverick biologists, such as Ernst T. Krebs, Sr. and Jr., H.H. Beard, William D. Kelley, DDS, and others.
Click or go to the following for information on Prof. John Beard:
http://www.cancerdecisions.com/062602.html
In recent years, academic scientists have identified cancer stems cells in blood cancers as well as in brain and breast tumors. The work of Michael Clarke, MD, and his post-doctoral student, Mohammed Al-Hajj, PhD, at the University of Michigan, has been particularly influential. Clarke and Al-Hajj have shown that, contrary to what is generally assumed, not all tumor cells are equally capable of causing metastatic cancer. In fact, they found that in experimental breast tumors only a tiny fraction - less than one percent - of tumor cells are actually capable of causing metastasis. These highly malignant cells are identifiable as stem cells.
Click or go here for information on Dr. Clarke's work:
http://www.cancerdecisions.com/042603.html
Research in 2005 by JeanMarie Houghton, MD, PhD, of the University of Massachusetts, Worcester, showed that in certain stomach cancers the cells that initiate the malignancy originate not in the tissues of the stomach itself, but are actually stem cells that have migrated there from the bone marrow. The initiating event in this sequence is a low-grade infection in the stomach, typically caused by Helicobacter pylori. Bone marrow derived cells (BMDCs) are sent to the stomach in response to this infection, as part of the body's attempt to heal itself. Once in the stomach, BMDCs assume the characteristics of the surrounding tissues, but under the influence of hormonal signals emitted by the inflamed tissue, they undergo malignant change.
Click on or go to the following addresses for information on Dr. Houghton's work:
http://www.cancerdecisions.com/022705.html
http://www.cancerdecisions.com/030605.html
TO BE CONCLUDED, WITH REFERENCES, NEXT WEEK.
--Ralph W. Moss, PhD
|
If you have cancer,
you may wish to fight it on 3 levels: 1) self-treatment
using the information on this website, 2) alternative
treatments available from a naturopath or other alternative
physician, 3) conventional medicine. To prepare yourself for
an encounter with a naturopath, oncologist, etc., you would be well advised to read the Moss
Report for your particular cancer. Dr. Moss has written a report for
each of over 200 different cancers, covering conventional as well as
alternative treatment options. - Editor, Alkalize For Health
Order Your Moss Report Now
If you or a loved one is dealing with cancer, you can
securely order a Moss Report right now by going to the
Cancer Decisions website. Your Moss Report will be delivered
in electronic format to your email inbox within minutes.
Created by Ralph W. Moss, PhD, a leading author and
consultant on cancer treatment, The Moss Report provides a
detailed, yet very readable explanation of your particular
cancer diagnosis. Each 400+ page report contains Dr. Moss's
top recommendations of the most successful treatments in
North America, Mexico, and Europe; as well as innovative
therapies that you really should know about.
You save by ordering a
downloadable report!
To order one immediately and securely, just click
here to proceed to the Cancer Decisions website. You
will be able to view a list of over 200 specific Moss
Reports as well as Dr. Moss’ introductory letter and a
sample Table of Contents.
|
***
-------------------------------------------------------
Ralph W. Moss, Ph.D. Weekly CancerDecisions.com
Newsletter #179 04/10/05
-------------------------------------------------------
THE MOSS REPORTS
In last week's newsletter I began a discussion of new research that indicates that stem cells may ultimately lie at the root of many kinds of cancer. I conclude that discussion this week.
It has been said, humorously, that no scientific theory gains public acceptance until it has been thoroughly discredited.
For almost a hundred years the ideas of the Scottish embryologist John Beard concerning the origin of cancer have languished in the dusty stack rooms of medical history, spurned by modern oncology in favor of newer theories. But increasingly it is becoming apparent that long before molecular biology was born, Beard may have hit upon a core truth.
While Beard himself would not have been aware of the existence of stem cells, his theory concerning the origins of cancer is remarkably compatible with the concept of stem cells as the source of malignancy.
It is also curiously satisfying, in a way, that it should be an extract of the humble cottage garden plant feverfew that researchers have found to be lethal to the malignant stem cells that cause acute and chronic myelogenous leukemia. The use of botanical extracts in medicine is as old as medicine itself, and it is encouraging to see that their potential is once again being harnessed for the benefit of cancer patients.
For thirty years I have been studying and writing about cancer treatments, both conventional and alternative. The fruit of my long career in this field is The Moss Reports, a comprehensive library of more than two hundred reports on specific cancer diagnoses. For cancer patients, a Moss Report represents an invaluable guide and handbook for the journey ahead.
If you would like to order a Moss Report for yourself or someone you love, you can do so from our
website, or by calling Diane at 1-800-980-1234 (814-238-3367 from outside the US).
We look forward to helping you.
FEVERFEW AND CANCER, PART II
The latest University of Rochester findings on feverfew, while interesting from the point of view of pharmacology, are even more important in terms of basic science. They have deepened the scientific understanding of how stem cells are involved in the origin and progression of cancer.
Currently, other treatments for AML, including the recently approved drug Gleevec, are only moderately effective. That may be because they do not affect the malignant stem cells, so "you're pulling the weed without getting to the root," as Dr. Craig T. Jordan of the University of Rochester said. In laboratory experiments, the Rochester scientists have now shown that parthenolide is in fact more selective at stopping cancer through apoptosis (programmed cell death) than was the standard drug cytarabine (Ara-C).
There have been some prior experiments showing that feverfew compounds halt the growth of cancer cells. A phase I trial found that it was also relatively non-toxic, laying the groundwork for future studies of its effectiveness (Curry 2004).
Feverfew Available
According to a University of Rochester press release, a person with leukemia would not be able to take enough of the over-the-counter herbal remedy to halt the disease. It is not clear how this information has been established in the absence of clinical trials. In fact, patients with leukemia might want to discuss this information with their hematologist-oncologist.
Standardized feverfew products are widely available for the treatment of migraine and other conditions. Many brands describe their products as "high parthenolide." One needs to read the labels carefully, however. I have found various products claiming to have 2, 5 or even 7 percent parthenolide by weight. Some of these come from obscure companies. One should definitely look for a product marketed by a reputable company which would have something substantial to lose by deceiving the public about the strength and purity of its product.
One such company is Nature's Way. This company markets three separate feverfew products: feverfew leaves, feverfew extract and an even more concentrated product called MygraFew. This claims to have a standardized content of 2 percent parthenolide. Thus, a 30 milligram tablet contains 600 micrograms of parthenolide.
Cautions
The label cautions that feverfew is not recommended for use by pregnant or lactating women, or children under two years of age. Certain individuals may also experience oral discomfort or irritation when using the product. If irritation does occur, the manufacturer advises discontinuing the use of the product immediately. According to the website www.intelihealth.com:
"Feverfew has been well tolerated in studies. The most common side effects are mouth inflammation or ulcers, including swelling of the lips, bleeding of the gums, and loss of taste. When stopped suddenly after being used for long periods of time, feverfew may cause rebound headaches, anxiety, sleep disturbances, muscle stiffness or pain. Some people may experience more rapid or pounding heart rates. Skin irritation or eczema may occur in those with feverfew allergies. Photosensitivity (sensitivity to sunlight or sunlamps) has been reported with other herbs in the Compositae plant family and may be possible with feverfew as well. Less common side effects may include stomach upset, such as indigestion, nausea, gas, constipation, diarrhea, bloating or heartburn."
It is not at all clear how often these adverse events occur. The website further cautions that feverfew may combine adversely with certain drugs:
"In theory, feverfew may increase the risk of bleeding when used with anticoagulants (blood thinners) or anti-platelet drugs. Examples include warfarin (Coumadin), heparin and clopidogrel (Plavix). Feverfew may also increase the risk of bleeding when used with anti-inflammatory pain relievers, such as aspirin, ibuprofen (Motrin, Advil) and naproxen (Naprosyn, Aleve, Anaprox). However, it is possible that feverfew may increase the effectiveness of these pain relievers.
"Based on the results from some animal studies, it has been suggested that feverfew could worsen symptoms of depression or reduce the effectiveness of antidepressants such as fluoxetine (Prozac). Feverfew should be used with caution in individuals with a history of depression or other psychiatric illnesses."
The current research work on the use of feverfew in the treatment of AML is extremely good news. Apart from anything else, it strengthens the argument that what is at the root of cancer is not a transformed body (somatic) cell, but a special type of stem cell. This concept has the potential to revolutionize the understanding of cancer, and its treatment.
However, even with the help of NCI, it may be years before this flower derivative makes it to the market. One thing is certain. At around 20˘ per tablet, the cost is reasonable, and compares favorably with patented Gleevec, which, although better researched, costs around $100 per day.
National Debate
There is a major national debate in the US over stem cell research. The use of stem cells has been restricted by government decree.
The National Institutes of Health (NIH) in principle is in favor of stem cell research. An NIH news release states:
"Research involving human pluripotent stem cells...promises new treatments and possible cures for many debilitating diseases and injuries. The NIH believes the potential medical benefits of human pluripotent stem cell technology are compelling and worthy of pursuit in accordance with appropriate ethical standards."
Yet there is a curious lack of support for stem cell research, at least at NCI. For instance, when I searched the NCI's financial year 2006 budget proposal I could find only one glancing reference to stem cells in that entire document.
I could also find no references whatsoever to stem cells in Andrew C. von Eschenbach's "A vision for the National Cancer Program in the United States." This is the statement in which the NCI director put forward his views on how to eliminate the death and suffering due to cancer by the year 2015. "A new era is now within our grasp," he stated, "a time when no one suffers or dies as a result of cancer." It is hard to imagine how the NCI intends to accomplish this without a serious involvement in the most important and exciting research initiative of our time.
--Ralph W. Moss, PhD
=======================
References:
Curry EA 3rd, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs. 2004;22:299-305
von Eschenbach AC. A vision for the National Cancer Program in the United States. Nat Rev Cancer. 2004;4:820-8. Retrieved February 22, 2004 from:
http://www.medscape.com/viewarticle/491395_1
Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005 Feb 1; [Epub ahead of print]
Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189-92
Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia. 2002;22:523-32
------------------------------------------------
IMPORTANT DISCLAIMERS
The news and other items in this newsletter are intended for informational purposes only. Nothing in this newsletter is intended to be a substitute for professional medical advice.
Copyright (C) The Internet Society (2004). This document is subject to the rights, licenses and restrictions contained in BCP 78, and except as set forth therein, the authors retain all their rights.
This document and the information contained herein are provided on an "AS IS" basis and THE CONTRIBUTOR, THE ORGANIZATION HE/SHE REPRESENTS OR IS SPONSORED BY (IF ANY), THE INTERNET SOCIETY AND THE INTERNET ENGINEERING TASK FORCE DISCLAIM ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY THAT THE USE OF THE INFORMATION HEREIN WILL NOT INFRINGE ANY RIGHTS OR ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
This document may not be modified, and derivative works of it may not be created.
-----------------------------------------------
IMPORTANT NOTICE:
If you have questions or concerns, please use our form at
http://www.cancerdecisions.com/contact.html
Thank you.
To SUBSCRIBE TO OUR FREE NEWSLETTER: Please go to
http://cancerdecisions.com/list/optin.php?form_id=8
and follow the instructions to be automatically added to this list.
Thank you.
=====
CancerDecisions®
PO Box 1076
Lemont, PA 16851
Phone Toll Free: 800-980-1234
If calling from outside the USA: 814-238-3367
FAX: 814-238-3367
=====
|
